Dr. Torres grew up as a poor farmer in the high mountains of Adjuntas, Puerto Rico, raising his farm animals and working before and after school at a small coffee plantation to support his entire family. A true pioneer in his rural community, he is a first-generation high school, college, graduate school, and university scholar. This challenging upbringing has influenced his entire life and career, and today he is a champion and an international leader of initiatives improving global access to education and healthcare.

Dr. Torres is a professor of the Department of Medical Microbiology and Immunology at UC Davis. When he founded CancerMune, he taught Medical Immunology to medical students and Human Immunology and Human Virology to advanced undergraduates. His entrepreneurial drive predates his venture with CancerMune. In 2001, he founded and presided over Variation Biotechnologies Inc. (now VBI Vaccines), a biotechnology company dedicated to developing new vaccines and improving existing vaccines. This company successfully grew, went public in 2014, and is currently listed in the NASDAQ stock exchange (VBIV).

In 2002, Dr. Torres Co-Founded the Sonora Cancer Research Center to advance immunotherapies' clinical applications for cancer. The following year, he was awarded the prestigious Roche-Syntex Rosenkranz Award for his pioneering use of research in using immunology in medicine and initiatives to improve health care access. He is a Fellow of the American Association for the Advancement of Science, a Professor of the UC Davis NCI-designated Comprehensive Cancer Center, and a member of the Executive Committee of the Center for Vectorborne Diseases (CVEC) Center of Excellence at the UC Davis School of Veterinary Medicine. Dr. Torres serves on the editorial boards of several scientific publications and has written or co-written more than 50 scientific articles.

After eight years of decorated military service as a US Marine and a combat tour to Iraq, where he was awarded for his outstanding leadership skills and contributions to his unit, he followed his calling to medicine and committed to making a difference for veterans who suffered traumatic brain injuries (TBIs). His desire to better understand TBIs led him to join the Ph.D. program in neuroscience at UC Berkeley.

At Berkeley, he received the prestigious Graduate Research Fellowship from the National Science Foundation to support his work. His scientific curiosity and contagious energy led him to establish collaborations with researchers at UCSF and Stanford. He studied epilepsy with Dr. Allyson Alexander, a neurosurgeon at the Stanford Hospital. Alexander also invited him to her operating room to show him how she used the latest technology to care for patients with brain tumors. These experiences taught him that neurosurgery was a promising path to achieve his goals. To learn more about translating research into clinical practice, he joined the Brain Trauma Foundation after graduation as the Assistant Program Manager for Guidelines to create TBI management guidelines. It then became clear that he needed to pursue a career as a physician-scientist to maximize his ability to help patients.

At UC Davis, Dr. Vazquez was awarded the Sandra L. Reed Scholarship and the Dean's Scholarship multiple times while he expanded his clinical skills and rediscovered his passion for patient-centered care. Dr. Vazquez's academic interests in neurosurgery continued to mature after completing three neurosurgical sub-internships with Honors at UC Davis, Stanford, and Yale. To support his neurosurgical training, he was awarded the Stanford Clinical Opportunity for Residency Experience Scholarship. As graduation approached, his desire to serve more patients than he could while caring for one patient at the time compelled him to set aside his neurosurgical ambitions and fully commit to lead CancerMune as CEO.

To fully dedicate her time and energy to advancing biomedical science, Dr. Tenborg completed a research fellowship with the Department of Comparative Medicine at the Stanford University School of Medicine. While at Stanford, Dr. Tenborg studied the interactions of pathogens with their host's immune system to describe the ways that microorganisms can control their host's response to infections.

Energized by her scientific discoveries at Stanford, Dr. Tenborg joined Metabiota and worked on Big data analytics to improve global resilience to epidemics by creating computational models, guidelines, and preparedness training for global health threats. This work paved the way for her follow-up transition to the United Nations (UN), where she built upon her work and contributed to meaningful global health initiatives. At the UN, Dr. Tenborg worked with global health leaders' multinational and multidisciplinary teams to draft the UN Global Rinderpest Action Plan.

After a successful mission with the UN, Dr. Tenborg returned to California to tackle a Virulent Newcastle disease (VND) outbreak affecting a community close to her heart. She joined the California Department of Food and Agriculture and the United States Department of Agriculture VND Taskforce to help contain the epidemic. Dr. Tenborg especially enjoyed helping the people of her home state of California and thus decided to transition her service career to working at a community-based practice. She served the Napa Valley communities, where she provided the highest quality of veterinary medicine to everyone who came to her clinic, including historically underserved communities and clients who could not afford veterinary services for their pets.

A committed scientist and entrepreneur, Dr. Tenborg co-founded CancerMune and began advancing its mission of developing innovative immunotherapies for cancers in dogs and humans as the Chief Veterinary Officer. Collaborating with teams at the UC Davis Mouse Biology Program and the School of Veterinary Medicine, Dr. Tenborg supervises all animal trials in CancerMune's drug development pipeline.

As a dermatologist, she committed herself to serve the poor and medically underserved populations of patients who shared with her a humble and challenged upbringing within Chinese society. As a clinician, Li always received praise from her patients, mentors, and peers. However, the powerless feeling that almost all clinical workers encounter in China led her to pursue more advanced clinical and scientific training. She completed a Master's program at the prestigious Shanghai Medical College of Fudan University, consistently ranked among the top three medical schools in China. She completed a Master of Science in Pathogen Biology with the honorary recognition of the "Excellent Graduation Dissertation" award. Eventually, She completed a Ph.D. in Pathogen Biology from the Shanghai Medical College of Fudan University.

In 2011, she moved to California after receiving a postdoctoral fellowship to join the Department of Medical Microbiology and Immunology at UC Davis, where she worked with Distinguished Professor Emeritus Murray B. Gardner, MD, and Jose V. Torres, Ph.D., in the development of candidate vaccines against human immunodeficiency viruses (HIV). Her passion for relieving patients' pain has never changed. Upon completing her postdoctoral fellowship in 2013, Dr. Li continued researching the efficacy of variable peptide vaccines at UC Davis and helped develop various candidate vaccines against oncogenic viruses that are core components of CancerMune's intellectual property portfolio.

Immediately after completing his Ph.D., Dr. Sepúlveda returned to his alma mater, UPRM, to work at the Industrial and Science Engineering department. There he started developing his research portfolio in data analytics, machine learning, and operations research. Concomitantly, he taught Probability and Statistics, Statistical Quality Control, Operations Research, and Reliability Engineering to graduate and advanced undergraduate students. Years later, the Hewlett-Packard Company (HP) offered him the unique opportunity to join their team to implement the concepts that he developed in research and improve their manufacturing operations in Puerto Rico.

At HP, Dr. Sepúlveda created and implemented data analysis and reporting systems to identify and track manufacturing process improvement opportunities. He also pioneered machine-learning algorithms that analyzed large sets of consumer data to develop recommendations for cross-selling and up-selling products and services at HP's global sales website (i.e., hp.com). His contributions to HP's operational effectiveness and sales were significant and earned him a promotion as a corporate internet and marketing data miner and quality engineer. In this position, he created some of HP's proprietary artificial-intelligence tools to analyze and develop actionable sales and marketing recommendations that influenced company-wide policies and initiatives.

The success of his initiatives inspired him to create his entrepreneurial endeavors, and in 2006 he founded Pronto Analytics. With his engineering team, Dr. Sepúlveda created a niche within the artificial-intelligence (AI) industry where he develops multi-platform data management and analysis applications for any large and complex data sets. His AI applications provide reliable solutions to common customer needs, such as creating customized databases, developing prediction models, performing image processing, and applying data mining techniques to generate business information as custom automated reports or dashboards.

He joined CancerMune to leverage his leadership and expertise in Statistical Data Modeling, Reliability Analysis, Statistical Quality Control, Business Intelligence, Image Processing, Data Mining, and Business Analytics in a humanitarian venture that promises to help cancer patients globally. He is applying his AI tools to improve and develop novel immunoinformatics algorithms for antigen prediction to develop therapeutic vaccines. In 2020, Dr. Sepúlveda's innovative computer science work was lauded with the Wolfram Innovator Award.